Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2

(2022) Rana Gbyli et al.   LEUKEMIA

Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors

(2022) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis

(2021) Sang Ik Park et al.   EUROPEAN RADIOLOGY

The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance

(2021) Nalin Leelatian et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Evidence-based recommendations on categories for extent of resection in diffuse glioma

(2021) Philipp Karschnia et al.   EUROPEAN JOURNAL OF CANCER

Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping

(2021) Kazuya Motomura et al.   JOURNAL OF NEURO-ONCOLOGY

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

(2021) Martin J van den Bent et al.   LANCET ONCOLOGY

A vaccine targeting mutant IDH1 in newly diagnosed glioma

(2021) Michael Platten et al.   NATURE

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas

(2021) Yao Yu et al.   NEURO-ONCOLOGY

MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas

(2021) Craig Horbinski et al.   NEURO-ONCOLOGY

Clinical Presentation and Management of SMART Syndrome

(2021) Sebastian F. Winter et al.   NEUROLOGY

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

(2021) Ingo K. Mellinghoff et al.   CLINICAL CANCER RESEARCH

Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).

(2021) Min Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).

(2021) Francois Ducray et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer

(2021) Emre Kocakavuk et al.   NATURE GENETICS

The implications of IDH mutations for cancer development and therapy

(2021) Christopher J. Pirozzi et al.   Nature Reviews Clinical Oncology

The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study

(2021) Tamara Ius et al.   NEURO-ONCOLOGY

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors

(2021) Tobias Walbert et al.   NEURO-ONCOLOGY

Oligosarcomas, IDH-mutant are distinct and aggressive

(2021) Abigail K. Suwala et al.   ACTA NEUROPATHOLOGICA

Back to the Future: Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past

(2021) Michelle M. Kim et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

(2021) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib

(2021) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

(2020) Daniel J. Brat et al.   ACTA NEUROPATHOLOGICA

Seizures in patients with cancer

(2020) L. Nicolas Gonzalez Castro et al.   CANCER

Making heads or tails – the emergence of capicua ( CIC ) as an important multifunctional tumour suppressor

(2020) Derek Wong et al.   JOURNAL OF PATHOLOGY

Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma

(2020) William G Breen et al.   NEURO-ONCOLOGY

Awake glioma surgery: technical evolution and nuances

(2020) Andrew J. Gogos et al.   JOURNAL OF NEURO-ONCOLOGY

Mechanisms and therapeutic implications of hypermutation in gliomas

(2020) Mehdi Touat et al.   NATURE

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence

(2020) Radhika Mathur et al.   NEURO-ONCOLOGY

Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment

(2020) Raymond Y Huang et al.   NEURO-ONCOLOGY

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas

(2020) Yuxiang Wang et al.   Science Advances

Infratentorial IDH-mutant astrocytoma is a distinct subtype

(2020) Rouzbeh Banan et al.   ACTA NEUROPATHOLOGICA

Impact of repeated operations for progressive low-grade gliomas

(2020) Ben Shofty et al.   EJSO

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

(2020) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

(2020) Erica H. Bell et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple motor mapping: transcranial, bipolar, and monopolar mapping for supratentorial glioma resection adjacent to motor pathways

(2020) Andrew J. Gogos et al.   JOURNAL OF NEUROSURGERY

CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

(2020) Kurt A Jaeckle et al.   NEURO-ONCOLOGY

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells

(2020) Hiroaki Nagashima et al.   Cancer Discovery

Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas

(2020) Marco Rossi et al.   NEURO-ONCOLOGY

Pulse sequences for measuring exchange rates between proton species: From unlocalised NMR spectroscopy to chemical exchange saturation transfer imaging

(2020) Eleni Demetriou et al.   PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY

Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis

(2020) Abigail K. Suwala et al.   ACTA NEUROPATHOLOGICA

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

(2020) Michael Weller et al.   Nature Reviews Clinical Oncology

Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype

(2020) Maria Diaz et al.   NEUROLOGY

Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up

(2020) P. Roth et al.   ANNALS OF ONCOLOGY

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus

(2019) David Schiff et al.   NEURO-ONCOLOGY

Genomic correlates of disease progression and treatment response in prospectively characterized gliomas

(2019) Philip Jonsson et al.   CLINICAL CANCER RESEARCH

Risk Factors For Childhood And Adult Primary Brain Tumors

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma

(2019) Shervin Tabrizi et al.   RADIOTHERAPY AND ONCOLOGY

Natural History and Growth Patterns of Incidentally Discovered Diffusely Infiltrating Low-Grade Gliomas: A Volumetric Study

(2019) Michael Opoku-Darko et al.   World Neurosurgery

Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016

(2019) Roberta Rudà et al.   JOURNAL OF NEURO-ONCOLOGY

Oligodendroglioma confers higher risk of radiation necrosis

(2019) Haroon Ahmad et al.   JOURNAL OF NEURO-ONCOLOGY

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

(2019) Dominique Farge et al.   LANCET ONCOLOGY

A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model

(2019) Yukino Machida et al.   MOLECULAR CANCER THERAPEUTICS

Longitudinal molecular trajectories of diffuse glioma in adults

(2019) Floris P. Barthel et al.   NATURE

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas

(2018) Mitsuaki Shirahata et al.   ACTA NEUROPATHOLOGICA

IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

(2018) Remco J. Molenaar et al.   CLINICAL CANCER RESEARCH

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

(2018) Lukas Bunse et al.   NATURE MEDICINE

Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas

(2018) Min Zhou et al.   NEURO-ONCOLOGY

A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence

(2018) Camila Ferreira de Souza et al.   Cell Reports

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

(2018) Samuel K. McBrayer et al.   CELL

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

(2018) Martin J van den Bent et al.   LANCET ONCOLOGY

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells

(2018) Mehmet G. Badur et al.   Cell Reports

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

(2017) Gary Kohanbash et al.   JOURNAL OF CLINICAL INVESTIGATION

Response Assessment in Neuro-Oncology Clinical Trials

(2017) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

(2017) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

(2017) Michael Weller et al.   LANCET ONCOLOGY

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence

(2017) Sevin Turcan et al.   NATURE GENETICS

Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy

(2017) Francesca Branzoli et al.   NEURO-ONCOLOGY

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

(2017) Maarten M J Wijnenga et al.   NEURO-ONCOLOGY

Mutant IDH1 and seizures in patients with glioma

(2017) Hao Chen et al.   NEUROLOGY

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutantIDH1

(2017) Tali Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

(2017) Andrew S. Venteicher et al.   SCIENCE

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

Mutant IDH1 and thrombosis in gliomas

(2016) Dusten Unruh et al.   ACTA NEUROPATHOLOGICA

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma

(2016) Changho Choi et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

(2016) Brigitta G Baumert et al.   LANCET ONCOLOGY

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis

(2016) T.-C. A. Johannessen et al.   MOLECULAR CANCER RESEARCH

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

(2016) Itay Tirosh et al.   NATURE

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics of gliomas in patients with somatic IDH mosaicism

(2016) Charlotte Bonnet et al.   Acta Neuropathologica Communications

CICinactivating mutations identify aggressive subset of 1p19q codeleted gliomas

(2015) Vincent Gleize et al.   ANNALS OF NEUROLOGY

Magnetic Resonance (MR) Metabolic Imaging in Glioma

(2015) Myriam M. Chaumeil et al.   BRAIN PATHOLOGY

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors

(2015) Tali Mazor et al.   CANCER CELL

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

(2015) O. C. Andronesi et al.   CLINICAL CANCER RESEARCH

Insulator dysfunction and oncogene activation in IDH mutant gliomas

(2015) William A. Flavahan et al.   NATURE

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

(2015) Macarena I. de la Fuente et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer

(2015) R. J. A. Bell et al.   SCIENCE

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth

(2015) Shenghong Ma et al.   Oncotarget

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

(2014) A. R. Grassian et al.   CANCER RESEARCH

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

(2014) H. Wakimoto et al.   CLINICAL CANCER RESEARCH

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting

(2013) Asgeir Store Jakola et al.   ACTA NEUROCHIRURGICA

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line

(2013) H. A. Luchman et al.   NEURO-ONCOLOGY

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry

(2013) A. N. Tran et al.   NEURO-ONCOLOGY

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

(2012) G. Jin et al.   CANCER RESEARCH

Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas

(2012) Asgeir S. Jakola et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

(2012) Robert B Jenkins et al.   NATURE GENETICS

Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments

(2012) R. Ruda et al.   NEURO-ONCOLOGY

Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy

(2012) O. C. Andronesi et al.   Science Translational Medicine

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

Factors associated with seizure freedom in the surgical resection of glioneuronal tumors

(2011) Dario J. Englot et al.   EPILEPSIA

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

(2011) MJ van den Bent et al.   LANCET ONCOLOGY

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome

(2011) Twinkal C Pansuriya et al.   NATURE GENETICS

Extent of Surgical Resection Predicts Seizure Freedom in Low-Grade Temporal Lobe Brain Tumors

(2011) Dario J. Englot et al.   NEUROSURGERY

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

(2011) Z. J. Reitman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Altered Telomeres in Tumors with ATRX and DAXX Mutations

(2011) C. M. Heaphy et al.   SCIENCE

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

(2009) Linda Douw et al.   LANCET NEUROLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE